3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Carcinoma, Transitional Cell
17
Neoplasms
6
Urologic Neoplasms
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Neoplasms by Site
3
Carcinoma in Situ
3
Carcinoma
3
Recurrence
2
Virus Diseases
1
Urothelial Carcinoma of the Bladder
1
Urothelial Carcinoma Ureter
1
Urogenital Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Recurrence, Local
1
Mycobacterium Infections
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Disease
1
Adenoviridae Infections
1
Interventions
Oncolytic Virotherapy
2
valrubicin
1
Mitomycin
1
Interferons
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Virus Diseases
×
Mitomycin
×
Genitourinary
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled